Bayforest Capital Ltd Acquires Shares of 15,033 LivaNova PLC $LIVN

Key Points

• Bayforest Capital Ltd has acquired 15,033 shares of LivaNova PLC, valued at approximately $590,000, during the first quarter of the year.
• Institutional investors hold a significant share of LivaNova, with approximately 97.64% of the company's stock owned by such entities.
• Analysts are optimistic about LivaNova's stock, with several raising their price targets, resulting in a consensus rating of "Buy" and a target price of around $59.71.

Bayforest Capital Ltd acquired a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,033 shares of the company's stock, valued at approximately $590,000.

Several other institutional investors have also bought and sold shares of LIVN. AQR Capital Management LLC lifted its position in LivaNova by 111.7% during the first quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company's stock valued at $60,809,000 after purchasing an additional 829,115 shares during the last quarter. Nuveen LLC bought a new position in LivaNova during the first quarter valued at $30,954,000. Hotchkis & Wiley Capital Management LLC lifted its position in LivaNova by 100.7% during the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,003,000 shares of the company's stock valued at $39,398,000 after purchasing an additional 503,350 shares during the last quarter. LSV Asset Management lifted its holdings in shares of LivaNova by 278.3% in the 1st quarter. LSV Asset Management now owns 438,498 shares of the company's stock worth $17,224,000 after acquiring an additional 322,598 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of LivaNova by 13.5% in the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock worth $104,755,000 after acquiring an additional 316,993 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on LIVN shares. Barclays raised their target price on shares of LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a research note on Tuesday, May 20th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, LivaNova presently has a consensus rating of "Buy" and a consensus price target of $59.71.

LivaNova Stock Up 0.7%

NASDAQ:LIVN opened at $58.72 on Wednesday. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The stock has a market capitalization of $3.21 billion, a P/E ratio of -15.10 and a beta of 0.96. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The company's 50-day simple moving average is $49.20 and its 200-day simple moving average is $43.80.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. The business had revenue of $352.50 million for the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company's revenue was up 10.6% compared to the same quarter last year. During the same period last year, the business earned $0.93 EPS. On average, equities analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.